Cyclacel Pharmaceuticals to Present at Rodman and Renshaw 3rd Annual Global Healthcare Conference.SHORT HILLS, N.J. -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC CYCC Canadian Youth Climate Coalition ) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the Company and its pipeline at the Rodman and Renshaw 3rd Annual Global Healthcare Conference in Monte Carlo Monte Carlo (môNtā` kärlō`), town (1982 pop. 13,150), principality of Monaco, on the Mediterranean Sea and the French Riviera. , Monaco. Cyclacel, which began trading on the Nasdaq National Market on March 28 and recently raised $45.3 million in a private placement, is focused on the discovery and development of small molecule cell cycle inhibitors for the treatment of cancer and other serious diseases. The Company's pipeline includes seliciclib (CYC202) and sapacitabine (CYC682), in clinical trials for the treatment of cancer, an aurora kinase Aurora kinases are serine/threonine kinases that are essential for cell proliferation. The enzyme helps the dividing cell share its genetic materials with its daughter cells. inhibitor (CYC116) in late preclinical development, a large portfolio of development candidates, and a productive drug discovery engine. Mr. Rombotis' presentation will take place on Monday, May 15, 2006 at 8:40 am Central European Summer Time Central European Summer Time (CEST) is one of the names of UTC+2 time zone, 2 hours ahead of Coordinated Universal Time. It is used as a summer daylight saving time in most European and some North African countries. During the winter, Central European Time (UTC+1) is used. in the Atlantique Salon - Western, located on the second floor of Le Meridien Beach Plaza Hotel The Plaza Hotel in New York City is a landmark 19-story luxury hotel with a height of 250 feet (76 m) and length of 400 feet that (122 m) occupies the west side of Grand Army Plaza, from which it derives its name, and extends along Central Park South in Manhattan. , 22 Avenue Princesse prin·cesse adj. Princess: a gown cut on princesse lines. [French, from Old French, princess; see princess.] Grace, Monte Carlo, Monaco. The presentation will be webcast live at: http://wsw.com/webcast/rrshq8/cycc. The webcast presentation will be available for 90 days. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. The Company is currently evaluating seliciclib (CYC202), an orally-available cyclin cy·clin n. A class of proteins that fluctuate in concentration at specific points during the cell cycle and that regulate the cycle by binding to a kinase. dependent kinase inhibitor, in Phase II clinical trials for the treatment of lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. . Sapacitabine (CYC682) is an orally-available, cell cycle modulating nucleoside nucleoside Any of a class of organic compounds, including structural subunits of nucleic acids. Each consists of a molecule of a five-carbon sugar (ribose in RNA, deoxyribose in DNA) and a nitrogen-containing base, either a purine or a pyrimidine. analog in Phase I clinical trials for the treatment of cancer. CYC116 is an orally-available, Aurora kinase inhibitor in IND-directed preclinical development. Several additional programs are at an earlier stage. Note: The Cyclacel logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc. Risk Factors This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements Capital requirements Financing required for the operation of a business, composed of long-term and working capital plus fixed assets. , and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the registration statement on Form S-4 (File No. 333-131225) and in the other reports of Cyclacel filed with the SEC. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion